Terremoto Biosciences Raises $108M Series C for AKT Drugs

Terremoto Biosciences, a California biotech, raised $108 million in a Series C financing to advance medicines targeting AKT for cancer and rare diseases. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, with existing backers OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management participating.

Terremoto has one therapy in Phase 1 testing for solid tumors with certain genetic alterations and expects another program to move into the clinic later in 2026. The company’s second candidate, TER-4480, is aimed at hereditary hemorrhagic telangiectasia, a rare bleeding disorder with no approved therapies.